Skip to Content


Active Substance: catumaxomab
Common Name: catumaxomab
ATC Code: L01XC09
Marketing Authorisation Holder: Neovii Biotech GmbH
Active Substance: catumaxomab
Status: Withdrawn
Authorisation Date: 2009-04-20
Therapeutic Area: Ascites Cancer
Pharmacotherapeutic Group: Other antineoplastic agents

Therapeutic Indication

Removab is indicated for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible.

The marketing authorisation for Removab has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.